Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis

Annals of Surgical Oncology

Volumn 14, Issue 8, 2007, Pages 2309-2318

  Lim, Sherry J ^a   Cormier, Janice N ^a   Feig, Barry W ^a   Mansfield, Paul F ^a   Benjamin, Robert S ^a   Griffin, Janet R ^a   Chase, Judy L ^a   Pisters, Peter W T ^a   Pollock, Raphael E ^a   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cisplatin; Cytoreduction; Hyperthermic intraperitoneal chemotherapy; Mitoxantrone; Sarcomatosis

Indexed keywords

CISPLATIN; MITOXANTRONE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ADVERSE OUTCOME; AGED; AMYLASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIC THERAPY; INFECTION; INTESTINE FUNCTION; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER FAILURE; LIVER TOXICITY; LUNG TOXICITY; MALE; METABOLIC DISORDER; MONOTHERAPY; NEPHROTOXICITY; OVERALL SURVIVAL; PANCREATITIS; PHASE 1 CLINICAL TRIAL; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; TEMPERATURE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; CLINICAL TRIALS, PHASE I; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MITOXANTRONE; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34547466644     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9463-z     Document Type: Article

References (54)

1. Ross JA, Severson RK, Davis S, Brooks JJ. Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987. Cancer 1993;72(2):486-90
2. Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 2006;119(12):2922-30
3. Cancer Facts and Figures 2006. American Cancer Society 2006
4. Ferrario T, Karakousis CP. Retroperitoneal sarcomas: grade and survival. Arch Surg 2003; 138(3):248-51
5. Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995; 221(4):392-7
6. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215(1):68-77
7. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350(9092):1647-54
8. Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg 1990; 212(1):51-9
9. Mendenhall WM, Zlotecki RA, Hochwald SN, et al. Retroperitoneal soft tissue sarcoma. Cancer 2005; 104(4):669-75
10. Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer 2002; 94(9):2441-6
11. Farma JM, Pingpank JF, Libutti SK, et al. Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg 2005; 9(9):1346-53
12. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240(2):278-85
13. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243(2):212-2
14. Kikuchi K, Yamagata S, Yoshizumi M, Watanabe R. [Evaluation of intraperitoneal perfusion of COPP in peritonitis carcinomatosis]. Gan No Rinsho 1965; 11(12):834-7
15. Vernick JJ, Oates GD, Magell J, Fried C. The use of anticancer agents for control of tumor growth in the peritoneal cavity after seeding with an experimental tumor. J Surg Res 1964; 4:559-61
16. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40(2):256-60
17. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106(9):1933-9
18. Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11(4):393-8
19. Mahteme H, Sugarbaker PH. Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin. Br J Surg 2004; 91(9):1168-73
20. Stewart JHt, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006; 13(5):624-4
21. Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27(3):239-43
22. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1):34-43
23. Abu-Surrah AS, Kettunen M. Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Curr Med Chem 2006; 13(11):1337-57
24. Kokufu I, Kurokawa E, Akashi H, et al. [Hepatic metastases from jejunal leiomyosarcoma treated effectively by repeated transarterial embolization with carboplatin]. Gan To Kagaku Ryoho 1993; 20(1):141-3
25. Mavligit GM, Zukiwski AA, Salem PA, et al. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer 1991; 68(2):321-3
26. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13(2):229-37
27. Muller H, Nakchbandi V. Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)-report of six cases. Eur J Surg Oncol 2004; 30(5):573-7
28. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22(16):3284-92
29. Dietel M, Arps H, Gerding D, et al. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin. J Cancer Res Clin Oncol 1988; 114(2):197-203
30. Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 1983; 10(2):103-15
31. Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 1990; 18(5):365-80
32. Schopman EM, Van Bree C, Bakker PJ, et al. Hyperthermia-enhanced effectiveness of mitoxantrone in an experimental rat tumour. Int J Hyperthermia 1996; 12(2):241-54
33. Wiedemann G, Mella O, Roszinski S, et al. Hyperthermia enhances mitoxantrone cytotoxicity on human breast carcinoma and sarcoma xenografts in nude mice. Int J Radiat Oncol Biol Phys 1992; 24(4):669-73
34. Eilber FC, Rosen G, Forscher C, et al. Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000; 9(2):71-5
35. Eilber FC, Rosen G, Forscher C, et al. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999; 6(7):645-50
36. Common Toxicity Criteria. Washington D.C.: National Cancer Institute, 1999
37. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473-83
38. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11(3):570-9
39. Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999; 35(3):413-9
40. Bonvalot S, Cavalcanti A, Le Pechoux C, et al. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur J Surg Oncol 2005; 31(8):917-23
41. Rossi CR, Deraco M, De Simone M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer 2004; 100(9):1943-50
42. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002; 94(2):492-9
43. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002; 13(2):267-72
44. Rossi CR, Mocellin S, Pilati P, et al. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am 2003; 12(3):781-94
45. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002; 13(3):181-209
46. Rufian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006; 94(4):316-24
47. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003; 10(8):863-9
48. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004; 139(1):20-26
49. Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138(1):26-33
50. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14(3):254-61
51. van der Vange N, van Goethem AR, Zoetmulder FA, et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000; 26(7):663-8
52. McQuellon RP, Loggie BW, Fleming RA, et al. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27(1):65-73
53. McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10(2):155-62
54. Mudan SS, Conlon KC, Woodruff JM, et al. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000; 88(1):66-74